Back to search

Peptide record

TPDB92194

FLAK50 Z4 Antibacterial Anticancer Antifungal Toxicity standard
22 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB92194
FLAK50 Z4
Antibacterial Anticancer Antifungal Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 Peptipedia ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 SATPdb iACP-DRLF CAFPdb dbAMP
standard
No
A 22-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, Peptipedia, ACP740 _ACP240, and other sources, with an available 3D structural model.
C-terminal: Amidation
Sequence
FAKLWAKLAFGKGIGKVGKKLL-NH2
Physicochemical Analysis
C117H193N29O23
RNDCEQHMPSTY
K
2374.00
11.21
6
0
12
+6
-1.12
0.409
115.45
Mammalian: 1.1 hour Yeast: 3 min E.coli: 2 min
5500
231.68
0
Residue Composition
number
3
A
0
R
0
N
0
D
0
C
0
E
0
Q
4
G
0
H
1
I
4
L
6
K
0
M
2
F
0
P
0
S
0
T
1
W
0
Y
1
V
Amino Acid Distribution
A: 3 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 4 H: 0 I: 1 L: 4 K: 6 M: 0 F: 2 P: 0 S: 0 T: 0 W: 1 Y: 0 V: 1
Chemical Descriptors
22
C117H193N29O23
2374.00
11.21
+6
-1.12
0.409
Amidation
L
Linear
Free
Anticancer
FLAK peptides
Evidence Records 6 records
Evidence 1 Activity

Activity

LD50
LD50 =54 µg/ml
Anticancer
54 µg/mL

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

LD50
LD50 =80 µg/ml
Anticancer
80 µg/mL

Target

Colon Cancer
SW-480
Colon

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 3 Activity

Activity

LD50
LD50 =155 µg/ml
Anticancer
155 µg/mL

Target

Skin Cancer
BMKC
Skin

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 4 Activity

Activity

LD50
LD50 =115 µg/ml
Anticancer
115 µg/mL

Target

Lung Cancer
H-1299
Lung

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 5 Activity

Activity

LD50
LD50 =310 µg/ml
Anticancer
310 µg/mL

Target

Prostate Cancer
PC-3
Prostate

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 6 Activity

Activity

LD50
LD50 =215 µg/ml
Anticancer
215 µg/mL

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT/MTS assay
24-h

Source & Reference

CancerPPD 2.0 SATPdb
CancerPPD2
2005
US_06875744_B2